2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2802

A Treat-To-Target Strategy With Methotrexate and Intra-Articular Triamcinolone With Or Without Added Adalimumab Reduces Synovitis, Osteitis and Tenosynovitis and Halts Structural Damage Progression In Early Rheumatoid Arthritis: The Opera Magnetic Resonance Imaging Sub-Study
Abstract Number: 777

A Unique Role For Galectin-9 In Angiogenesis and Inflammatory Arthritis
Abstract Number: 2383

A Useful Mathematical Model Able To Predict The Early Response To Tocilizumab In Rheumatoid Arthritis
Abstract Number: 1885

A Weighted Genetic Risk Score Using All Known Susceptibility Variants To Predict Rheumatoid Arthritis Risk
Abstract Number: 2349

Abatacept and Anti-Tumor Necrosis Factor Monoclonal Antibodies: Efficacy and Safety Comparisons
Abstract Number: 720

Abatacept Efficacy Is Overruled By IL-7 In TSLP-Primed Myeloid Dendritic cell driven T Cell Activation From Rheumatoid Arthritis Patients
Abstract Number: 723

Abatacept Is Highly Effective At Inhibiting T Cell Priming and Induces a Unique Transcriptional Profile In CD4⁺t Cells
Abstract Number: 522

Abatacept Reduces Disease Activity In Early Primary Sjögren’s Syndrome:One Year Results From a Phase II Open-Label Study
Abstract Number: 1175

ABCG2 May Influence Risk Of Gout Through Extra-Renal Metabolic Pathways: Analysis Of The Effects Of The Q141K Variant On Serum Urate Responses To a Fructose Load
Abstract Number: 1366

Abdominal Adiposity and Body Composition In Rheumatoid Arthritis: Relation With Disease Characteristics In A Case-Control Study
Abstract Number: 2196

Aberrant IgG Glycosylation Is Associated With Active Disease In Juvenile Idiopathic Arthritis Patients
Abstract Number: 1834

Abnormal Collagen Fibers Deposition In The Synovial Joints Is a Characteristic Of The Temporal Evolution Of The Diabetic rats’ Model Induced By Streptozotocin
Abstract Number: 307

Abnormal Imaging and Increased Osteoclast Precursors In a Psoriasis Cohort Are Associated with New Onset of Psoriatic Arthritis
Abstract Number: 2700

Abnormal Mitochondrial Electron Transport Chain Activity At Complex I Is Regulated By Nitric Oxide and N-Acetylcysteine In Lupus Lymphocytes
Abstract Number: 1087

Abnormalities Of Central Processing Mechanisms In Fibromyalgia

« Previous Page
1
…
5
6
7
8
9
…
193
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].